J.P. Morgan Day 4: Preparing For The Year Ahead
Daily notebook from the virtual J.P. Morgan Healthcare Conference: Updates from Galapagos, Ipsen, LG Chem, Hanmi and Fosun; experts discuss deal and financial outlook at Biotech Showcase, plus the impact of RMAT and the changing landscape for rare diseases.
You may also be interested in...
From a STING agonist to a SOS1 inhibitor, Lupin listed oncology candidates from the preclinical stage to those in IND-enabling studies during the recently concluded J.P. Morgan conference. Meanwhile, the newly spun-off oncology subsidiary awaits partners.
The power dynamics for deal-making in 2022 may shift to smaller companies emboldened by funds from venture financing and IPOs. While the spotlight will continue to be on ADCs and cell and gene therapies, vaccines and COVID-19 treatments will predictably be hot areas for licensing, Syneos Health predicts.
No big buyouts were revealed during the annual J.P. Morgan Healthcare Conference for a third year in a row. Big pharma firms are in acquisition mode, but execs stress desire for easy integrations and scientific alliances.